PTE: Forms Strategic Review Committee
Jan 11, 2021 14:01:04 GMT
thought013, c2crusher, and 1 more like this
Post by icemandios on Jan 11, 2021 14:01:04 GMT
PolarityTE Announces Formation of Strategic Review Committee
PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value. The committee will focus on reviewing operational strategies and practices that advance the regulatory process for SkinTE and future financings, if any, that may be helpful in advancing the Company’s strategies and making recommendations to the Board. The committee also has the authority to review the Company’s potential strategic opportunities and transactions that may arise in the future and make recommendations to the Board regarding those matters, as appropriate.
Peter Cohen, Chairman of the Board, commented, “The Board of Directors is committed to maximizing shareholder value and believes the Company’s lead asset, SkinTE, offers tremendous benefits to patients suffering from debilitating wounds.” Mr. Cohen continued, “The Board believes that, working with the FDA, the pursuit of a BLA for SkinTE is the right path to improving shareholder value in the future.”
About PolarityTE®
PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.
PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value. The committee will focus on reviewing operational strategies and practices that advance the regulatory process for SkinTE and future financings, if any, that may be helpful in advancing the Company’s strategies and making recommendations to the Board. The committee also has the authority to review the Company’s potential strategic opportunities and transactions that may arise in the future and make recommendations to the Board regarding those matters, as appropriate.
Peter Cohen, Chairman of the Board, commented, “The Board of Directors is committed to maximizing shareholder value and believes the Company’s lead asset, SkinTE, offers tremendous benefits to patients suffering from debilitating wounds.” Mr. Cohen continued, “The Board believes that, working with the FDA, the pursuit of a BLA for SkinTE is the right path to improving shareholder value in the future.”
About PolarityTE®
PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.